New Three-Drug cocktail aims to outsmart tough leukemia

NCT ID NCT06644183

Recruiting now Disease control Sponsor: Jennifer R. Brown, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of three drugs—roginolisib, venetoclax, and rituximab—in people with chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatments. The goal is to see if the combination is safe and can wipe out leukemia cells more effectively. About 64 participants will receive the drugs orally or by infusion, and researchers will measure how many achieve undetectable minimal residual disease in their bone marrow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Roginolisib (a targeted drug) combined with venetoclax and rituximab
What this could lead to: If successful, this combination could offer a more effective and tolerable treatment option for people with hard-to-treat CLL, potentially leading to longer remission without the need for continuous therapy.
What could go wrong: This is an early-phase trial with only 64 participants, so results may not apply to everyone. The drugs can cause side effects like liver issues, rash, diarrhea, and infections. The combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia Recurrence refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA LEUKEMIA REFRACTORY LEUKEMIA RELAPSED CANCER RELAPSED LEUKEMIA

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.